Cyteir Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2012-01-01
- Employees
- 46
- Market Cap
- -
- Website
- http://www.cyteir.com
A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors
Phase 1
Completed
- Conditions
- Multiple MyelomaSoft Tissue SarcomaHead and Neck CancerNon-hodgkin LymphomaOvarian CancerDLBCLMalignancyMantle Cell LymphomaCLLSquamous Cell Carcinoma of Head and Neck
- Interventions
- Drug: CYT-0851 in combination with gemcitabineDrug: CYT-0851 in combination with capecitabineDrug: CYT-0851 in combination with rituximab and bendamustine
- First Posted Date
- 2019-06-25
- Last Posted Date
- 2024-12-24
- Lead Sponsor
- Cyteir Therapeutics, Inc.
- Target Recruit Count
- 169
- Registration Number
- NCT03997968
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Stanford Comprehensive Cancer Center, Stanford, California, United States